Teladoc Health (TDOC), the global leader in virtual care, and Livongo (LVGO), the leading Applied Health Signals company – announced that they have entered into a definitive merger agreement.
Brings Together Highly Complementary Portfolios to Empower Clinicians and Patients in the Fight Against Cancer Establishes Integrated Platform of End-to-End Oncology Solutions to Address Entire Cancer Care Continuum – from Screening and Diagnosis to Care Delivery and Post-Treatment Survivorship Creates a Leading Digital Healthcare Platform that Leverages Real-World Evidence and AI, Positioning Combined Company to Favorably Disrupt Oncology Care with Software, Data and Technology Varian Shareholders to Receive $177.50 per Share in Cash, Representing a 42% Premium
Project taps DFC expertise and new partnership with DOD; Kodak’s heritage for innovation
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).
This is a joint press release of the Federal Ministry of Economics and Energy and dievini Hopp Biotech holding. A list of questions and answers regarding the investment of the German Federal Government can be found at the bottom of this page.
Company working on a number of agreements in parallel to ensure broad and equitable supply of the vaccine throughout the world at no profit during the pandemic. First agreements to supply at least 400 million doses; Company has total capacity sourced for one billion doses through 2020 and into 2021; continues to increase capacity further. More than $1bn US BARDA investment to support development and production of the vaccine.
Gedeon Richter Plc. ("Richter") today announced that it has entered into an asset purchase agreement with Mycenax Biotech Inc. ("Mycenax") in respect of biosimilar tocilizumab ("Product") for the treatment of rheumatoid arthritis.